<div id="readability-page-1"><p>Nordson Corporation ((NDSN)) has held its Q1 earnings call. Read on for the main highlights of the call.</p><h3>President's Day Sale - 70% Off</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Nordson Corporation opened fiscal 2026 on an upbeat note, delivering record quarterly sales, earnings and EBITDA while emphasizing disciplined execution and strong cash generation. Management acknowledged margin pressure from geographic mix, foreign exchange and a softer start in Medical, but framed these as manageable issues against a backdrop of robust demand and raised guidance.</p> <h2>Record First Quarter Sales</h2> <p>Nordson posted record Q1 sales of $669 million, up 9% from $615 million a year earlier, with organic growth of 7%. Management highlighted particularly strong demand in Asia, which led the growth profile, even as it brought some margin trade‑offs due to a heavier mix of system sales in that region.</p> <h2>Robust Advanced Technology Solutions Performance</h2> <p>The Advanced Technology Solutions segment stood out with sales of $149 million, climbing 23% year over year and 21% on an organic basis. EBITDA in ATS surged 43% to $33 million, lifting margin to 22%, powered by double‑digit electronics dispense growth and improving X‑ray inspection demand.</p> <h2>Profitability Records and Margin Resilience</h2> <p>Adjusted operating profit rose 10% to $166 million, while Q1 EBITDA reached a record $203 million, up 8% with margin holding around 30%. Adjusted EPS also set a first‑quarter record at $2.37, a 15% increase from $2.06, underscoring Nordson’s ability to protect profitability despite mix and FX headwinds.</p> <h2>Strong Free Cash Flow and Capital Deployment</h2> <p>Free cash flow came in at $123 million, with cash conversion running at 105% of net income excluding a non‑cash gain, signaling robust cash generation. The company balanced shareholder returns and investment, paying $46 million in dividends, repurchasing $82 million of stock and deploying $18 million in capital expenditures.</p> <h2>Improved Guidance and Backlog Momentum</h2> <p>Backlog entering the second quarter was roughly 4% higher than a year ago, giving visibility into near‑term demand. On this foundation, Nordson raised its outlook, guiding Q2 sales to $710–$740 million and adjusted EPS to $2.70–$2.90, while lifting full‑year sales and earnings expectations.</p> <h2>Balance Sheet Strength and Leverage Management</h2> <p>Nordson ended the quarter with $120 million in cash and net debt of about $1.9 billion, translating to a leverage ratio of 2.1 times, in line with its year‑end targets. A new credit facility adds roughly $800 million of available capacity, enhancing financial flexibility to pursue strategic acquisitions while maintaining balance sheet discipline.</p> <h2>One‑time Non‑Cash Investment Gain</h2> <p>Results included a $22 million pre‑tax non‑cash mark‑to‑market gain tied to a minority investment following an initial public offering. Management recorded this in other income and excluded it from adjusted earnings, aiming to preserve clarity around the company’s underlying operating performance.</p> <h2>Geographic and Product Mix Pressure on Margins</h2> <p>Growth skewed heavily toward Asia, where Nordson typically earns lower gross margins, especially on system‑heavy projects, weighing on incremental margins. The IPS segment felt this effect acutely, with EBITDA margin contracting by about 2 percentage points to 34% of sales compared with the prior year.</p> <h2>Medical &amp; Fluid Solutions Slow Start and Weather Disruption</h2> <p>Medical &amp; Fluid Solutions delivered $193 million in sales, essentially flat year on year, though organic growth was 3% before the impact of a divestiture. Severe winter storms late in January temporarily disrupted production and shipments, which management estimates shaved roughly 1% off quarterly sales.</p> <h2>Divestiture Impact on Comparables</h2> <p>Year‑over‑year comparisons in the Medical business were further complicated by the prior divestiture of a medical contract manufacturing operation. That sale reduced reported sales by about 4%, masking the underlying organic improvement and pressuring headline segment metrics.</p> <h2>Foreign Exchange as an Incremental Drag</h2> <p>Currency movements provided a top‑line lift, adding roughly 4% to total sales and about 6% to IPS revenue. However, management noted that FX benefits tend to carry low incrementals of only 25%–30%, which limited margin leverage and contributed to the modest year‑on‑year compression.</p> <h2>ATS Lumpy Systems Demand and Timing Risk</h2> <p>Despite its strong quarter, ATS remains exposed to the inherent lumpiness of large system orders, which depend heavily on customer installation timing. Management cautioned that this can create volatility from quarter to quarter even when demand and backlog trends remain solid, urging investors to focus on longer‑term trajectories.</p> <h2>Upgraded Outlook and Forward‑Looking Guidance</h2> <p>Buoyed by record Q1 results, expanding backlog and strong cash flow, Nordson raised its full‑year outlook for both sales and earnings. The company now expects fiscal‑year sales between $2.86 billion and $2.98 billion and adjusted EPS of $11.00–$11.60, with the high end reflecting sustained ATS momentum and an improving industrial backdrop.</p> <p>Nordson’s latest earnings call painted a picture of a company executing well, capitalizing on technology‑driven growth while managing through mix‑related and macro headwinds. With record profitability, healthy cash returns and a higher bar for 2026 performance, investors will be watching whether ATS strength broadens into other segments and supports the newly raised guidance.</p></div>

NDSN

<p>Nordson Corporation reported record Q1 results, with sales of $669 million, a 9% increase year-over-year. The Advanced Technology Solutions segment saw a 23% sales rise. Despite margin pressures from geographic mix and foreign exchange, adjusted EPS reached a record $2.37. Free cash flow was strong at $123 million, and the company raised its guidance for Q2 sales to $710–$740 million and full-year sales to $2.86–$2.98 billion. Nordson's balance sheet remains strong, with $120 million in cash and a leverage ratio of 2.1 times, supporting strategic acquisitions.</p>

Nordson Lifts 2026 Outlook After Record Q1